Immunodeficiency UK has launched a new national survey exploring the experiences of patients, carers, and healthcare professionals who have been affected by changes to immunoglobulin (IG) therapy.
Switches between IG products or delivery methods can happen for many reasons, from clinical needs or supply issues to NHS procurement updates. But these changes can have a real impact on patients' independence, confidence, and quality of life, as well as on the healthcare professionals who support them.
For healthcare professionals: your perspective counts
We are inviting healthcare professionals to share their insights through a dedicated survey, designed to capture the professional experience of managing IG therapy switches.
The survey asks about:
- Frequency and reasons for switches
- Involvement in decision-making
- Impact on patient wellbeing
- Communication with patients about switching
Your input will help highlight both the practical and ethical challenges of switching, as well as opportunities for improvement.
Take the survey here: https://form.typeform.com/to/TmHIo09b
Why this matters
This initiative aligns with NHS immunoglobulin framework targets — including the current phase of IVIg switching (September 2025) and SCIg switching (December 2025).
By combining patient and clinician perspectives, this research will help ensure that any future changes are guided by real-world experience and evidence.
Have your say
If you haven't yet taken part, please consider completing the survey. It only takes a few minutes to complete, and every response makes a difference.
Together, we can help ensure that future IG therapy switches are informed, transparent, and supportive for everyone involved.
October 2025
